## Your synthesis is largely correct — with three refinements

You have essentially reconstructed the **confirmatory research pipeline**:

> Define boundary → pre-specify claim → design unbiased test → control false positives → check robustness against counterpoints.

That is the right skeleton. But three parts need sharpening:

1. **“Case-control experiment (causality-based)”** is not quite right. Case-control is an **observational** design. It can support causal inference under strong assumptions, but it is not itself a causal experiment.
2. **Correlation-based data-driven research can be compelling — but “compelling” is not the same as “causal.”** Good design raises credibility; it does not automatically license causal language.
3. **Prospective vs retrospective** is a real and important axis, and it interacts with everything above.

## 1. Should logical thinking first define the research boundary?

**Yes. This is the correct first move, and it is routinely skipped.**

Defining the boundary means specifying, before analysis:

- **Question**: what exactly is being asked? (e.g., “Does treatment X change transcript Y in tissue Z?” not “What does treatment X do?”)
- **Population / system**: which samples, which organism, which tissue, which condition?
- **Claim type**: is this a **descriptive** claim (“X is correlated with Y”), a **predictive** claim (“X predicts Y”), a **causal** claim (“X causes Y”), or a **mechanistic** claim (“X causes Y via pathway P”)?
- **Scope of inference**: within the studied samples only, or generalized to a population?
- **What is out of scope**: which alternative explanations, which subgroups, which conditions are explicitly not addressed?

Why this matters logically: **scope creep after seeing results** is one of the most common ways a modest finding becomes an inflated claim. A boundary defined in advance is a contract you can be held to. A boundary defined after the fact is a story.

> **Boundary first, claim second, design third.** Reversing this order is how post-hoc narratives are born.

## 2. Pre-specify the major claim before experiments (avoiding leakage)

**Yes — for confirmatory research.** This is the core of pre-registration and preregistered analysis plans.

The logic:

- If you specify the claim and the test **before** seeing data, the test has a known error rate.
- If you specify them **after** seeing data, the “test” is contaminated by the data that motivated it — this is **leakage** in the broad sense (the analysis knows the answer).
- Leakage inflates false positives and makes p-values uninterpretable.

But there is a crucial nuance:

> **Exploratory research is legitimate. It just must not be reported as confirmatory.**

Data-driven exploration is how you **generate** hypotheses. The logical error is not exploration; it is **presenting an exploratory finding as if it were a pre-specified test**. The honest structure is:

- **Exploratory phase**: “We observed pattern P in dataset D. This is hypothesis-generating.”
- **Confirmatory phase**: “We pre-specified P and tested it in independent dataset D′.”

In omics, this is why **discovery / validation splits** and **independent replication cohorts** matter so much. The discovery set is the janitor; the validation set is the detective.

## 3. Designing an unbiased experiment and controlling false positives

**Yes — but “unbiased” is an aspiration, not an achievement.** You cannot exclude all confounders, because you cannot know all confounders. What you can do is:

- **Measure and adjust for known confounders** (batch, age, sex, library prep, sequencing depth, cell-type composition).
- **Randomize** assignment where possible (treatment vs control) to break confounding by design.
- **Blind** sample handling and analysis where possible.
- **Pre-specify** the primary endpoint and the multiplicity correction.
- **Include negative controls** (e.g., housekeeping genes, spike-ins, permuted labels).
- **Check robustness** with sensitivity analyses: does the claim survive alternative normalization, outlier removal, model choice?

The phrase “exclude known potential confounders” is right, but add: **unknown confounders are the residual risk**, and the defense against them is randomization, replication, and triangulation — not adjustment.

## 4. Can correlation-based data-driven research draw compelling conclusions?

**Yes — if “compelling” means “credible and useful,” not “causal.”**

Correlation-based research can be genuinely compelling when:

| Strengthening feature | Why it helps |
|---|---|
| Large effect size | Harder to explain by noise or weak confounding |
| Dose–response relationship | More consistent with a real underlying process |
| Replication across independent cohorts | Reduces chance of artifact |
| Temporal ordering (prospective cohort) | Exposure measured before outcome; rules out reverse causation |
| Confounder adjustment + sensitivity analysis | Addresses known alternative explanations |
| Biological plausibility + independent perturbation | Convergent evidence from a different modality |
| Natural experiment / Mendelian randomization | Uses exogenous variation as a quasi-randomization |

But even then, the logical claim should match the design:

- **Correlational design** → “X is associated with Y, robust to measured confounders.”
- **Quasi-experimental design** (MR, natural experiment) → “X likely has a causal effect on Y, under assumptions A, B, C.”
- **Randomized perturbation** (CRISPR, drug, knockout) → “X causes Y in this system.”

> **A well-designed correlation study can be highly compelling evidence for an association. It cannot, by itself, establish causation.** Causation requires either intervention, exogenous variation, or an explicit causal model with defended assumptions.

The mistake to avoid is not “doing correlation research.” The mistake is **using causal language for correlational evidence** — and the related mistake of **dismissing all correlational evidence as worthless**, which is equally illogical.

## 5. Prospective vs retrospective experiments

This is a real distinction, and it matters for validity and robustness.

| Dimension | Prospective | Retrospective |
|---|---|---|
| **Timing** | Hypothesis and design defined before data collection | Hypothesis defined after or during use of existing data |
| **Data source** | Newly collected, designed for the question | Existing data (biobank, EHR, GEO, TCGA, prior cohort) |
| **Confounder control** | Can measure what you need; can randomize | Limited to what was measured; unknown confounders likely |
| **Selection bias** | Lower, if sampling is well designed | Higher — the existing dataset was selected for some other reason |
| **Recall / measurement bias** | Can standardize | Depends on original study quality |
| **Cost / time** | High | Low |
| **Causal inference** | Stronger, especially with randomization | Weaker, unless natural experiment / MR / strong design |
| **Replication value** | Primary evidence | Often used for replication or discovery |
| **Main risk** | Expensive, slow, may fail | Confounding by indication, data quality, “dataset reuse” bias |

In omics:

- **Prospective**: a new cohort recruited with pre-specified exposure and outcome, standardized sample collection, uniform library prep.
- **Retrospective**: reanalysis of public RNA-seq from GEO, or EHR-linked biobank data. Powerful for discovery and replication, but the original data were not collected to answer your question — so **the design is inherited**, and so are its biases.

> **Rule of thumb:** prospective designs buy you control over confounders and timing; retrospective designs buy you scale and speed at the cost of inherited bias. Neither is automatically “better” — the right choice depends on whether your claim is exploratory, associational, or causal.

## Putting your synthesis together

Your proposed pipeline, corrected:

1. **Define the boundary** — question, population, claim type, scope, out-of-scope alternatives.
2. **Pre-specify the claim and the test** — before data, to avoid leakage. (Exploration is allowed, but must be labeled.)
3. **Choose the design** — prospective vs retrospective; observational vs perturbation; data-driven vs hypothesis-driven — matching the design to the **claim type**.
4. **Control what you can** — randomization, blinding, confounder measurement, batch design, negative controls, multiplicity correction.
5. **Test robustness** — sensitivity analyses, replication, triangulation across data types.
6. **Match language to evidence** — association language for correlational designs; causal language only when the design supports it.

> **The key logical move you identified correctly:** the design must be capable of producing evidence that would count against the claim. A design that cannot fail is not a test. But “capable of failing” does not require exhausting all alternatives — it requires a **discriminating prediction** and a **fair comparison**.

Ready for Phase 2? Any questions or wonderings so far?